Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Pharmacokinetic characterization of krca-0008 as a novel potent and selective anaplastic lymphoma kinase inhibitor for anticancer treatment

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: AHN, Sung-Hoon (Kangwon National University, College of Pharmacy, Chuncheon, Korea, Republic Of)
  • Co-author(s): Sung-Hoon Ahn: College of Pharmacy, Kangwon National University, Chuncheon, Korea, Republic Of
  • Abstract:

    Background

    KRCA-0008, bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines, has been under development as a potent and selective Anaplastic lymphoma kinase (ALK) and Ack1 dual inhibitor for anti-cancer treatment. KRCA-0008 has in vivo efficacy with a modest tumor growth inhibition in xenograft mice model bearing H3122 human lung..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses